Author

S. Venkat

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:differential expression· 4 Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Research Focus:gene regulatory network inference· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

M. E. Feigin· 3 shared A. A. Alahmari· 2 shared A. A. Tisdale· 2 shared A. C. Cornwell· 1 shared A. H. Chaubey· 1 shared A. Hill· 1 shared B. S. Katzenellenbogen· 1 shared C. A. Natale· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. E. Feigin

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Development of a high-throughput barrier function assay using primary human gut organoids

C. W. Wright, N. Li, L. Shaffer, A. Hill, N. Boyer, S. Alves, S. Venkat, K. Biswas, L. A. Lieberman, S. Mohammadi

The paper develops a high-throughput assay using primary human gut organoids to assess barrier function and response to TNF-α, showing dose-dependent rescue by antagonists.

bioRxiv · Dec 16, 2022 · PreprintImmunology

CPSF3 inhibition blocks pancreatic cancer cell proliferation through disruption of core histone processing

A. A. Alahmari, A. H. Chaubey, A. A. Tisdale, C. D. Schwarz, A. C. Cornwell, K. E. Maraszek, E. J. Paterson, M. Kim, S. Venkat, E. Cortes Gomez, J. Wang, K. V. Gurova, M. E. Feigin

This study identifies CPSF3 as a druggable target in pancreatic cancer by showing its inhibition disrupts histone processing and cell proliferation.

bioRxiv · May 9, 2022 · PreprintCancer Biology

Alternative polyadenylation characterizes epithelial and fibroblast phenotypic heterogeneity in pancreatic ductal adenocarcinoma

S. Venkat, M. E. Feigin

The paper identifies 3 UTR-APA patterns in PDAC single-cell data, linking them to metastatic epithelial and inflammatory fibroblast subpopulations and phenotypic heterogeneity.

bioRxiv · Sep 18, 2021Cancer Biology

CHRM1 is a Druggable Melanoma Target Whose Endogenous Activity is Determined by Inherited Genetic Variation in DOPA Production

M. Doepner, C. A. Natale, I. Y. Lee, S. Venkat, S. H. Kim, J. A. Katzenellenbogen, B. S. Katzenellenbogen, M. Feigin, T. W. Ridky

This study identifies CHRM1 as a druggable melanoma target influenced by genetic variation in DOPA production, showing DOPA inhibits CHRM1 to suppress melanoma proliferation.

bioRxiv · Mar 3, 2021 · PreprintCancer Biology

Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma

S. Venkat, A. A. Tisdale, J. R. Schwarz, A. A. Alahmari, H. C. Maurer, K. P. Olive, K. H. Eng, M. E. Feigin

This study identifies APA-driven gene expression changes in pancreatic ductal adenocarcinoma, revealing miRNA loss and therapeutic targets like CK1.

bioRxiv · Aug 30, 2019Cancer Biology